These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 23281248

  • 1. High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine.
    Johannsen KH, Handrup MM, Lausen B, Schrøder H, Hasle H.
    Pediatr Blood Cancer; 2013 Jul; 60(7):1154-60. PubMed ID: 23281248
    [Abstract] [Full Text] [Related]

  • 2. Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group.
    Lewis V, Yanofsky R, Mitchell D, Dix D, Ethier MC, Gillmeister B, Johnston D, Michon B, Stobart K, Portwine C, Silva M, Cellot S, Price V, Bowes L, Zelcer S, Brossard J, Beyene J, Sung L.
    Pediatr Infect Dis J; 2014 Feb; 33(2):126-9. PubMed ID: 24064558
    [Abstract] [Full Text] [Related]

  • 3. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia.
    Brunet AS, Ploton C, Galambrun C, Pondarré C, Pages MP, Bleyzac N, Freydière AM, Barbé G, Bertrand Y.
    Pediatr Blood Cancer; 2006 Nov; 47(6):765-72. PubMed ID: 16333838
    [Abstract] [Full Text] [Related]

  • 4. Clinical features and complications of viridans streptococci bloodstream infection in pediatric hemato-oncology patients.
    Huang WT, Chang LY, Hsueh PR, Lu CY, Shao PL, Huang FY, Lee PI, Chen CM, Lee CY, Huang LM.
    J Microbiol Immunol Infect; 2007 Aug; 40(4):349-54. PubMed ID: 17712470
    [Abstract] [Full Text] [Related]

  • 5. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
    Lech-Maranda E, Seweryn M, Giebel S, Holowiecki J, Piatkowska-Jakubas B, Wegrzyn J, Skotnicki A, Kielbinski M, Kuliczkowski K, Paluszewska M, Jedrzejczak WW, Dutka M, Hellmann A, Flont M, Zdziarska B, Palynyczko G, Konopka L, Szpila T, Gawronski K, Sulek K, Sokolowski J, Kloczko J, Warzocha K, Robak T.
    Int J Infect Dis; 2010 Feb; 14(2):e132-40. PubMed ID: 19581118
    [Abstract] [Full Text] [Related]

  • 6. [Infection control in neutropenia induced by high-dose cytarabine chemotherapy].
    Miyazaki M, Senzaki K, Kiyoi H, Kohno S, Noda Y, Nabeshima T.
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2011-5. PubMed ID: 15570930
    [Abstract] [Full Text] [Related]

  • 7. In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices.
    Paulus S, Dobson S, Rassekh S, Blondel-Hill E.
    J Pediatr Hematol Oncol; 2009 Apr; 31(4):267-9. PubMed ID: 19346878
    [Abstract] [Full Text] [Related]

  • 8. Infections with viridans group streptococci in children with cancer.
    Reilly AF, Lange BJ.
    Pediatr Blood Cancer; 2007 Nov; 49(6):774-80. PubMed ID: 17588233
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Development and validation of a clinical model to predict the presence of β-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients.
    Shelburne SA, Lasky RE, Sahasrabhojane P, Tarrand JT, Rolston KV.
    Clin Infect Dis; 2014 Jul 15; 59(2):223-30. PubMed ID: 24755857
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience.
    Radocha J, Paterová P, Zavřelová A, Víšek B, Gabalec F, Žemličková H, Žák P.
    Folia Microbiol (Praha); 2018 Mar 15; 63(2):141-146. PubMed ID: 28776170
    [Abstract] [Full Text] [Related]

  • 16. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T, Sugiyama T, Nakao S, Origasa H, Umehara H, Ueda T.
    Anticancer Res; 2012 Feb 15; 32(2):643-7. PubMed ID: 22287757
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia.
    Okamoto Y, Ribeiro RC, Srivastava DK, Shenep JL, Pui CH, Razzouk BI.
    J Pediatr Hematol Oncol; 2003 Sep 15; 25(9):696-703. PubMed ID: 12972804
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.